Streetbeat News

ELV

Elevance Health Inc.

https://www.elevancehealth.com

Industry

Medical - Healthcare Plans

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Open

405.00

Mkt cap

93B

Volume

2.6M

High

408.58

P/E Ratio

14.58

52-wk high

567.26

Low

398.69

Div yield

0.02

52-wk low

397.98

Morgan Stanley has maintained its Overweight rating for Elevance Health (NYSE:ELV) and increased its price target from $571.00 to $585.00. Elevance Health, a leading health insurer in the U.S., is unique as the largest single provider of Blue Cross Blue Shield branded coverage. The company's reach expands beyond 14 states through government-sponsored programs such as Medicaid and Medicare Advantage plans.

Portfolio Pulse from Benzinga Insights

July 25, 2023 | 5:00 pm

Morgan Stanley analyst Michael Ha has maintained an Overweight rating on Elevance Health (NYSE:ELV) and raised the price target from $571 to $585.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2023 | 12:25 pm

Elevance Health (NYSE:ELV) has received mostly bullish ratings from analysts in the last quarter, with an average price target of $564.71, a 0.09% decrease from the previous average price target of $565.20. There were no bearish or indifferent ratings.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 9:00 pm

TD Cowen analyst Gary Taylor maintains an Outperform rating on Elevance Health (NYSE:ELV) and raises the price target from $564 to $585.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 24, 2023 | 4:29 pm

Elevance Health's (NYSE:ELV) short percent of float has fallen 11.69% since its last report, with 1.62 million shares sold short, which is 0.68% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards the stock. Compared to its peers, Elevance Health has less short interest as a percentage of float, with an average of 3.54%.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 3:45 pm

Elevance Health (NYSE:ELV) reported a loss in earnings of $1.86 billion in Q2, but sales increased by 3.53% to $43.38 billion. The company posted a Return on Capital Employed (ROCE) of 0.05%, indicating effective capital allocation. Elevance Health's Q2 earnings per share were $9.04, beating analyst predictions of $8.8.

Portfolio Pulse from Benzinga Insights

July 20, 2023 | 2:46 pm

RBC Capital analyst Ben Hendrix has reiterated an Outperform rating on Elevance Health (NYSE:ELV) and maintained a price target of $572.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 1:58 pm

Stephens & Co. analyst Scott Fidel has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a price target of $555.

Portfolio Pulse from richadhand@benzinga.com

July 20, 2023 | 1:08 pm

Unusual options activity has been observed for Elevance Health (NYSE:ELV), with a large position indicating a bullish stance. The sentiment among these big-money traders is split between 60% bullish and 40% bearish. The whales have been targeting a price range from $350.0 to $550.0 for Elevance Health over the last 3 months. The price of ELV is up 4.93% at $465.56, and RSI indicators suggest the stock may be approaching overbought.

Portfolio Pulse from Benzinga Insights

July 19, 2023 | 7:01 pm

The article lists the stocks that have gained and lost the most in Wednesday's mid-day session. Among the gainers, Biodexa Pharmaceuticals, SMX, Carvana, and Panbela Therapeutics saw significant increases due to various reasons such as patent allowances, better-than-expected sales, and asset divestitures. Among the losers, Sono Group, Amarin Corporation, Aqua Metals, and Aptevo Therapeutics saw significant decreases due to reasons such as delisting notices, organizational restructuring, and public offerings.

Portfolio Pulse from Lisa Levin

July 19, 2023 | 5:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.